Abstract
Fetal hemoglobin (HbF) has been developed into an important alternative protein for oxygen therapeutics. Such applications require extensive amounts of proteins, which only can be achieved via recombinant means. However, the expression of vertebrate hemoglobins in heterologous hosts is far from trivial. There are several issues that need to be dealt with. These include, among others, the solubility of the globin chains, equimolar expression of the globin chains, and access to high levels of free heme. In this study, we examined the impact of introducing negative charges on the surface of HbF. Three different HbF mutants were examined, carrying four additional negative charges on the α-subunit (rHbFα4), two additional negative charges on the γ-subunit (rHbFγ2) or a combination of these (rHbFα4/γ2). The increase in negative surface charge in these HbF mutants required the development of an alternate initial capture step in the downstream purification procedures. For the rHbFα4 mutant, we achieved a significantly enhanced yield of purified HbF with no apparent adverse effects on Hb functionality. However, the presence of non-functional Hb portions in the rHbFγ2 and rHbFα4/γ2 samples reduced the yields significantly for those mutants and indicated an imbalanced expression/association of globin chains. Furthermore, the autoxidation studies indicated that the rHbFγ2 and rHbFα4/γ2 mutants also were less oxidatively stable than rHbFα4 and wt rHbF. The study further verified the need for an improved flask culture protocol by optimizing cultivation parameters to enable yield-improving qualities of surface-located mutations.
Highlights
Blood transfusion is a routine and lifesaving clinical intervention in many fields, including emergency medicine, advanced surgery, and cancer treatment
Three HbF mutants with an increased negative net charge at physiological pH were successfully produced in E. coli
Retention behavior shifts observed during chromatographic procedures strongly indicated the increased negative net surface charge on the HbF mutants
Summary
Blood transfusion is a routine and lifesaving clinical intervention in many fields, including emergency medicine, advanced surgery, and cancer treatment. The shortage of blood donors and the risk of bloodborne pathogens have in many instances hampered regular surgical procedures. Alternatives to blood that can complement and reduce the demands on blood have long been sought after in medicine. Several potential agents have been proposed including hemoglobin-based oxygen carriers (HBOC)s (Alayash 1999) and perfluorocarbons (Castro and Briceno 2010). The development of these agents has largely been constrained by safety issues and a lack of efficient large-scale recombinant production systems (Alayash 2014).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.